Event

PIE Day

Date: Tuesday, March 10, 2026
Location: Conshohocken, PA
Cencora HQ

PIE Day - What is it?

A live, invite-only, half-day event for biopharma companies where Cencora will unveil our annual payer market insights on pre-approval information exchange (PIE), provide opportunities to engage payers and in-house experts in interactive discussions on best-practices and case studies, and create a venue for networking with industry peers.  

When: Tuesday, March 10, 2026 - From 10:00am to 3:00pm
Where: Cencora Headquarters, Conshohocken, PA 

Space is limited and registration will close on January 30, 2026.  

Why should biopharma companies attend?

This event is a must-attend for biopharma professionals looking to optimize their Pre-Approval Information Exchange (PIE) strategies and drive successful product launches.

What you'll gain

  • Get exclusive access to Cencora’ s proprietary market insights on PIE derived from payer market research and in-house subject matter experts. Insights include: the latest payer preferences for PIE, content considerations, formats and timing for delivery, and specific considerations for different product types and company sizes (e.g., large, established, emerging, pre-commercial) 
  • Hear directly from payers on their expectations for PIE and engage directly with them in a small group setting 
  • Review case studies and discuss best practices to design best-in-class PIE strategies to optimize a product launch 

Why it matters 

Payers continue to report a gap in the pre-approval resources they need from biopharma companies. To help bridge this gap, Cencora has conducted annual payer market research on PIE for nearly a decade to equip biopharma companies with the latest and most actionable insights to inform their PIE strategies and tactics. Getting PIE right is incredibly important. Here is what payers have said:1 

  • Patient access to products may be accelerated 
  • Formulary decision-making and contracting discussions are improved 
  • Coverage decisions can be directly impacted  

Who should attend?

Individuals working at biopharma companies, with responsibilities for PIE planning and execution for products launching in the next 12-18 months – including both new product and new indication launches. 

Optimize your pre-approval information exchange (PIE) approach

The PIE Act, part of the 2023 Consolidated Appropriations Act, allows biopharma companies to share key data with healthcare decision-makers (HCDMs) before FDA approval. This proactive engagement is crucial for successful commercialization. Cencora helps biopharma overcome challenges by delivering timely, tailored information to strengthen relationships and position products for success.

Additional information

  • Attendance at the event is complimentary for biopharma companies; however, attendees are responsible for covering their own travel and lodging expenses, if applicable
  • While there is no cost for biopharma companies to attend the event, attendees are responsible for their own expenses for travel and lodging, if needed
  • Space is limited, and registration will close on January 30, 2026  
  • Breakfast and lunch will be provided to all attendees during the event

Footnote:

1. Cencora PayerPulse: The benefits of engaging in pre-approval information exchange (PIE)
https://www.cencora.com/resources/pharma/cencora-payerpulse-benefits-of-engaging-pie

Connect with our team

We empower our customers to bring their innovations to patients worldwide. By combining deep expertise with a global range of solutions, we deliver critical insights and transformative results for our pharmaceutical partners. Connect with our experts today!

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.